<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2d1 20170631//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article" dtd-version="1.2d1" specific-use="production" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MEDRXIV</journal-id>
<journal-title-group>
<journal-title>medRxiv</journal-title>
<abbrev-journal-title abbrev-type="publisher">medRxiv</abbrev-journal-title>
</journal-title-group>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1101/2020.12.10.20240069</article-id>
<article-version>1.1</article-version>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>Radiology and Imaging</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Drug-coated balloons for dysfunctional hemodialysis venous access: A patient-level meta-analysis of randomized controlled trials</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Yung</surname><given-names>Fong Khi</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="author-notes" rid="n1">&#x002A;</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhao</surname><given-names>Joseph J</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="author-notes" rid="n1">&#x002A;</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tan</surname><given-names>Eelin</given-names></name>
<degrees>BMed, MD</degrees>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a4">4</xref>
<xref ref-type="author-notes" rid="n1">&#x002A;</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Syn</surname><given-names>Nicholas</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="author-notes" rid="n1">&#x002A;</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Sultana</surname><given-names>Rehena</given-names></name>
<degrees>MSc</degrees>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhuang</surname><given-names>Kun Da</given-names></name>
<degrees>MBBS, FRCR, MMed</degrees>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Chua</surname><given-names>Jasmine</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Ming</surname><given-names>Er</given-names></name>
<degrees>MBBS, FRCR, MMed</degrees>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Patel</surname><given-names>Ankur</given-names></name>
<degrees>BMedSc, MB ChB, MRCS, FRCR, MMed, FAMS</degrees>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Irani</surname><given-names>Farah Gillan</given-names></name>
<degrees>MBBS, FRCR</degrees>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hiong</surname><given-names>Tay Kiang</given-names></name>
<degrees>MBBS, FRCR, FAMS</degrees>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Soo</surname><given-names>Tan Bien</given-names></name>
<degrees>MBBS, FRCR, FAMS</degrees>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Wei</surname><given-names>Too Chow</given-names></name>
<degrees>MBBS, FRCR, MMed, FAMS</degrees>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a4">4</xref>
<xref ref-type="author-notes" rid="n1">&#x002A;</xref>
<xref ref-type="corresp" rid="cor1">&#x0023;</xref>
</contrib>
<aff id="a1"><label>1</label><institution>Yong Loo Lin School of Medicine, National University of Singapore</institution>, <country>Singapore</country></aff>
<aff id="a2"><label>2</label><institution>Department of Vascular &#x0026; Interventional Radiology, Singapore General Hospital</institution>, <country>Singapore</country></aff>
<aff id="a3"><label>3</label><institution>Division of Radiological Sciences, Singapore General Hospital</institution>, <country>Singapore</country></aff>
<aff id="a4"><label>4</label><institution>Radiological Sciences Academic Clinical Program, SingHealth-Duke-NUS Academic Medical Centre</institution>, <country>Singapore</country></aff>
<aff id="a5"><label>5</label><institution>Centre for Quantitative Medicine, Duke-NUS Graduate Medical School</institution>, <country>Singapore</country></aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>&#x0023;</label><bold>Corresponding author:</bold> Adjunct Assistant Professor Too Chow Wei, MBBS, FRCR, MMed, FAMS, Department of Vascular &#x0026; Interventional Radiology, Singapore General Hospital, Singapore Division of Radiological Sciences, Singapore General Hospital, Singapore, Radiological Sciences Academic Clinical Program, SingHealth-Duke-NUS Academic Medical Centre, Singapore, Outram Road, Singapore 169608, <email>too.chow.wei@singhealth.com.sg</email></corresp>
<fn id="n1" fn-type="equal"><label>&#x002A;</label><p>These authors contributed equally</p></fn>
</author-notes>
<pub-date pub-type="epub">
<year>2020</year>
</pub-date>
<elocation-id>2020.12.10.20240069</elocation-id>
<history>
<date date-type="received">
<day>10</day>
<month>12</month>
<year>2020</year>
</date>
<date date-type="rev-recd">
<day>10</day>
<month>12</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>12</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2020, Posted by Cold Spring Harbor Laboratory</copyright-statement>
<copyright-year>2020</copyright-year>
<license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nd/4.0/"><license-p>This pre-print is available under a Creative Commons License (Attribution-NoDerivs 4.0 International), CC BY-ND 4.0, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nd/4.0/">http://creativecommons.org/licenses/by-nd/4.0/</ext-link></license-p></license>
</permissions>
<self-uri xlink:href="20240069.pdf" content-type="pdf" xlink:role="full-text"/>
<abstract>
<title>ABSTRACT</title>
<sec>
<title>Purpose</title>
<p>To perform an individual patient data-level meta-analysis of randomized controlled trials comparing drug-coated balloon angioplasty (DCB) against conventional percutaneous transluminal angioplasty (PTA) in the treatment of dysfunctional hemodialysis venous access.</p></sec>
<sec>
<title>Methods</title>
<p>A search was conducted from inception till 13<sup>th</sup> November 2020. Kaplan-Meier curves comparing DCB to PTA by target lesion primary patency (TLPP) and access circuit primary patency (ACPP) were graphically reconstructed to retrieve patient-level data. One-stage meta-analyses with Cox-models with random-effects gramma-frailties were conducted to determine hazard ratios (HRs). Dynamic restricted mean survival times (RMST) were conducted in view of violation of the proportional hazards assumption. Conventional two-stage meta-analyses and network meta-analyses under random-effects Frequentist models were conducted to determine overall and comparative outcomes of paclitaxel concentrations utilised. Where outliers were consistently detected through outlier and influence analyses, sensitivity analyses excluding those studies were conducted.</p></sec>
<sec>
<title>Results</title>
<p>Among 10 RCTs (1,207 patients), HRs across all models favoured DCB (one-stage shared-frailty HR=0.62, 95&#x0025;-CI: 0.53&#x2013;0.73, P&#x003C;0.001; two-stage random-effects HR=0.60, 95&#x0025;-CI: 0.42&#x2013;0.86, P=0.018, <italic>I</italic><sup><italic>2</italic></sup>=65&#x0025;) for TLPP. Evidence of time-varying effects (P=0.005) was found. TLPP RMST was &#x002B;3.47 months (25.0&#x0025;) longer in DCB-treated patients compared to PTA (P=0.001) at 3-years. TLPP at 6-months, 1-year and 2-years was 75.3&#x0025; vs 58.0&#x0025;, 51.1&#x0025; vs 37.1&#x0025; and 31.3&#x0025; vs 26.0&#x0025; for DCB and PTA respectively. P-Scores within the Frequentist network meta-analysis suggest that higher concentrations of paclitaxel were associated with better TLPP and ACPP. Among 6 RCTs (854 patients), the one-stage model favoured DCB (shared-frailty HR=0.72, 95&#x0025;-CI: 0.60&#x2013;0.87, P&#x003C;0.001) for ACPP. Conversely, the two-stage random-effects model demonstrated no significant difference (HR=0.76, 95&#x0025;-CI: 0.35&#x2013;1.67, P=0.414, <italic>I</italic><sup><italic>2</italic></sup>=81&#x0025;). Sensitivity analysis excluding outliers significantly favoured DCB (HR=0.61, 95&#x0025;-CI: 0.41&#x2013;0.91, P=0.027, <italic>I</italic><sup><italic>2</italic></sup>=62&#x0025;).</p></sec>
<sec>
<title>Conclusion</title>
<p>Overall evidence suggests that DCB is favoured over PTA in TLPP and ACPP. The increased efficacy of higher concentrations of paclitaxel may warrant further investigation.</p></sec>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>Individual patient-data meta-analysis</kwd>
<kwd>Hemodialysis Access Circuit</kwd>
<kwd>Drug-coated Balloon</kwd>
<kwd>Paclitaxel-coated Balloon</kwd>
<kwd>Conventional Balloon Angioplasty</kwd>
<kwd>Meta-analysis</kwd>
<kwd>Target Lesion Primary Patency</kwd>
<kwd>Access Circuit Primary Patency</kwd>
</kwd-group>
<counts>
<page-count count="48"/>
</counts>
</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>Joseph J Zhao is supported by the SingHealth SMSTDA Talent Development Award administered by SingHealth, Singapore and NUS Enterprise Innovation and Entrepreneurship Practicum Award awarded by National University of Singapore, Singapore.</p></notes>
<notes notes-type="financial-disclosure">
<title>Funding Statement</title><p>No external funding was received.</p></notes>
<notes notes-type="disclosures">
<title>Author Declarations</title><p>I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.</p><p>Yes</p><p>The details of the IRB/oversight body that provided approval or exemption for the research described are given below:</p><p>NA</p><p>All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.</p><p>Yes</p><p>I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).</p><p>Yes</p><p>I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.</p><p>Yes</p></notes>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Venous stenosis is the commonest cause of dysfunction in arteriovenous fistulas (AVFs) and arteriovenous grafts (AVGs) used for hemodialysis [<xref ref-type="bibr" rid="c1">1</xref>]. The Kidney Disease Outcomes Quality Initiative (KDOQI) recommends percutaneous transluminal angioplasty (PTA) as first-line treatment to restore vessel patency [<xref ref-type="bibr" rid="c2">2</xref>]. While PTA procedural success is generally high, microscopic damage to the vessel wall upon inflation may cause reactive intimal hyperplasia [<xref ref-type="bibr" rid="c3">3</xref>-<xref ref-type="bibr" rid="c5">5</xref>], inducing restenosis and poor long-term patency [<xref ref-type="bibr" rid="c6">6</xref>].</p>
<p>Presently, drug-coated balloon (DCB) angioplasty has become an increasing subject of discussion as an adjunct to PTA. DCBs are commonly coated with paclitaxel, which prevents neointimal hyperplasia in blood vessels [<xref ref-type="bibr" rid="c7">7</xref>-<xref ref-type="bibr" rid="c9">9</xref>].</p>
<p>Paclitaxel DCB has been demonstrated to be superior to PTA in the contexts of femoropopliteal artery disease [<xref ref-type="bibr" rid="c10">10</xref>] and coronary instent restenosis [<xref ref-type="bibr" rid="c11">11</xref>]. However, findings are mixed in the setting of hemodialysis access &#x2013; some meta-analyses significantly favoured DCB over PTA [<xref ref-type="bibr" rid="c12">12</xref>, <xref ref-type="bibr" rid="c13">13</xref>], while others reported no significant benefit [<xref ref-type="bibr" rid="c14">14</xref>, <xref ref-type="bibr" rid="c15">15</xref>]. Not long ago, two new randomized controlled trials (RCTs) on this subject were published [<xref ref-type="bibr" rid="c16">16</xref>, <xref ref-type="bibr" rid="c17">17</xref>]; this article aims to re-evaluate the field with these new inclusions. To our knowledge, this is first meta-analysis which includes these 2 new RCTs.</p>
<p>In lieu of this area&#x2019;s uncertain and developing nature, more precise methods are needed to quantify the comparison between DCB and PTA. Thus, we utilised graphical reconstructive algorithms to attain survival information of individual patients [<xref ref-type="bibr" rid="c18">18</xref>, <xref ref-type="bibr" rid="c19">19</xref>] from Kaplan-Meier curves. Individual patient data (IPD) is recognised as the gold standard approach for evidence synthesis [<xref ref-type="bibr" rid="c20">20</xref>, <xref ref-type="bibr" rid="c21">21</xref>]. The source of IPD for this study was restricted to RCTs only, as baseline characteristic differences between patients and differing indications for treatment render non-randomized studies difficult to interpret definitively.</p>
<p>Leveraging the IPD of 11 RCTs, this meta-analysis aims to compare the relative efficacy of DCB to PTA in maintaining target lesion primary patency (TLPP) and access circuit primary patency (ACPP) in hemodialysis patients with stenosed venous access.</p>
</sec>
<sec id="s2">
<title>Methodology</title>
<sec id="s2a">
<title>Literature Search</title>
<p>The electronic literature search was conducted on EMBASE, Scopus, PubMed and Web of Science for RCTs from inception to 13<sup>th</sup> November 2020 using a search string [<bold>Supplementary Table 1</bold>], in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Cochrane Guidelines (PRISMA) for IPD and network meta-analysis (NMA) [<xref ref-type="bibr" rid="c22">22</xref>, <xref ref-type="bibr" rid="c23">23</xref>]. Only full-text articles were included. If the same publication appeared more than once, the most recent publication was used for the analysis.</p>
<p>We included RCTs reporting TLPP and ACPP between DCB and PTA that provided Kaplan-Meier curves. The exclusion criteria for this study were: (a) Studies only comparing differences within a single approach. (b) Studies with combination approaches including multiple intra-arterial approaches.</p>
<p>For studies with multiple treatment arms, we only analysed the treatment arms in our inclusion criteria. The abstracts were reviewed by 3 investigators J.J.Z., K.Y.F. and E.T. and conflicts resolved by C.W.T. The data was extracted by K.Y.F., J.J.Z. and E.T. using predefined data fields including study characteristics, patient demographics and primary endpoints.</p>
</sec>
<sec id="s2b">
<title>Risk of Bias Assessment</title>
<p>The RCTs were assessed for risk of bias by K.Y.F. and J.J.Z. using the Cochrane Risk of bias (RoB 2) tool for RCTs [<xref ref-type="bibr" rid="c24">24</xref>]. Studies were also assessed for trustworthiness and relevance with the Joanna Briggs Institute (JBI) critical appraisal tool for RCTs [<xref ref-type="bibr" rid="c25">25</xref>].</p>
</sec>
<sec id="s2c">
<title>Statistical Analysis</title>
<sec id="s2c1">
<title>Reconstruction of Individual Patient Data</title>
<p>Prior to meta-analyses, we reconstructed IPD from published survival curves using a graphical reconstructive algorithm by Guyot et al [<xref ref-type="bibr" rid="c18">18</xref>]. Images of Kaplan-Meier curves from included studies were digitised to obtain the step function values and timings of the steps. Survival information of individual patients were then recovered based on the numerical solutions to the inverted Kaplan-Meier product-limit equations [<xref ref-type="bibr" rid="c18">18</xref>]. The IPD dataset was reconstructed by J.J.Z and K.Y.F. and were approved by E.T. by visual comparisons against original curves, and comparing reconstructed raw hazard ratio (HR) and P-values to reported values [<bold>Supplementary Table 2, Supplementary Comparisons 1, 2</bold>].</p>
</sec>
<sec id="s2c2">
<title>One-Stage Meta-Analysis</title>
<p>The Kaplan-Meier method was used to determine TLPP and ACPP for both groups. To account for between-study heterogeneity, Cox-models with random-effects gamma-frailties and stratification were conducted to determine HRs of patients undergoing DCB versus PTA. The primary analysis was based on a shared-frailty approach which assumes that individual patients are at an equal risk of death as other individuals within the same study. Then, we stratified the Cox model by study subgroups, modelling inter-study heterogeneity by assuming a baseline hazard amongst patients in each unique study.</p>
<p>For Cox-based models, we verified the proportional hazards (PH) assumption by examining scaled Schoenfeld residuals [<xref ref-type="bibr" rid="c26">26</xref>] and through the quantitative Grambsch-Therneau test [<xref ref-type="bibr" rid="c27">27</xref>]. Where the PH assumption was violated, we analysed restricted mean survival times (RMST) and modelled patency outcomes at prespecified epochs up to 1-, 2- and 3-years [<xref ref-type="bibr" rid="c28">28</xref>]. RMST is an alternative treatment outcome measure that can be estimated as the area under the survival curve up to a prespecified time horizon and hence can account for all survival information before that time horizon [<xref ref-type="bibr" rid="c28">28</xref>, <xref ref-type="bibr" rid="c29">29</xref>]. To fully capture the dynamic changes of RMST differences and ratios, we computed RMST values over a range of values to the restriction time (tau) to trace out an evolving treatment effect profile over time [<xref ref-type="bibr" rid="c30">30</xref>].</p>
<p>Patency rates were calculated from the one-stage meta-analysis along with Greenwood 95&#x0025; confidence intervals to account for censorship status. To account for the group of patients who no longer contribute to excess hazard (as seen by long plateaus on Kaplan-Meier curves), we fitted flexible parametric cure models to estimate &#x201C;long term patency rates&#x201D; using an identity link [<xref ref-type="bibr" rid="c31">31</xref>].</p>
</sec>
<sec id="s2c3">
<title>Two-Stage Meta-Analysis</title>
<p>We computed summary HRs for individual studies based on the reconstructed individual patient dataset and pooled them under a conventional two-stage Frequentist meta-analysis. The random-effects model was chosen in light of the high degree of heterogeneity found (<italic>I</italic><sup><italic>2</italic></sup>). <italic>I</italic><sup><italic>2</italic></sup> can be interpreted as the disparity in study results due to between-study variability. In light of the potentially high degree of clinical heterogeneity of included studies (as evidenced by differences in inclusion criteria, paclitaxel dose concentrations, proportions of AVFs versus AVGs and devices utilised), a random-effects model was used. Quantitative analysis of funnel plot asymmetry was done using Egger&#x2019;s regression test [<xref ref-type="bibr" rid="c32">32</xref>]. Heterogeneity was considered low, moderate, or considerable for <italic>I</italic><sup><italic>2</italic></sup> values &#x003C;40&#x0025;, 40-75&#x0025;, and &#x003E;75&#x0025; respectively [<xref ref-type="bibr" rid="c33">33</xref>, <xref ref-type="bibr" rid="c34">34</xref>]. Where considerable heterogeneity was found, we searched for extreme effect sizes (outliers) using outlier and influence analysis [<xref ref-type="bibr" rid="c35">35</xref>, <xref ref-type="bibr" rid="c36">36</xref>]. Where outliers were consistently detected across these analyses, sensitivity analyses excluding those studies were conducted.</p>
</sec>
<sec id="s2c4">
<title>Frequentist Network Meta-Analysis</title>
<p>Where concentration of paclitaxel was provided, natural log-transformed hazard ratios were estimated for each IPD study and were pooled together in an NMA within a Frequentist setting. Treatment strategies were ranked using P-Scores, with higher P-Scores corresponding to greater efficacy [<xref ref-type="bibr" rid="c37">37</xref>].</p>
</sec>
<sec id="s2c5">
<title>Meta-Regression</title>
<p>To identify potential sources of heterogeneity, we performed a meta-regression with aggregate level data. Prior to meta-regression, we imputed missing means and standard deviations (SDs) from medians, ranges (minimum to maximum), and interquartile ranges (IQRs) using the methods proposed by Hozo et al [<xref ref-type="bibr" rid="c38">38</xref>], Wan et al [<xref ref-type="bibr" rid="c39">39</xref>] and Furukawa et al [<xref ref-type="bibr" rid="c40">40</xref>]. Conventional mixed effects meta-regression of variables (with more than 10 studies) were performed against logarithmic transformed hazard ratios.</p>
<p>All analyses were conducted in R-4.0.0 (with packages &#x2018;digitize&#x2019;, &#x2018;survival&#x2019;, &#x2018;flexsurvcure&#x2019;, &#x2018;metafor&#x2019;. &#x2018;dmetar&#x2019; and &#x2018;netmeta&#x2019;). P &#x003C; 0.05 were regarded to indicate statistical significance.</p>
</sec>
</sec>
</sec>
<sec id="s3">
<title>Results</title>
<sec id="s3a">
<title>Study Selection</title>
<p>The search strategy retrieved 503 studies; after de-duplication and screening, 11 RCTs [<xref ref-type="bibr" rid="c16">16</xref>, <xref ref-type="bibr" rid="c17">17</xref>, <xref ref-type="bibr" rid="c41">41</xref>-<xref ref-type="bibr" rid="c48">48</xref>] comprising 1,243 patients were eligible and included in the meta-analysis [<bold><xref rid="fig1" ref-type="fig">Figure 1</xref></bold>]. One RCT was excluded as no curve was provided for graphical reconstruction to retrieve patient-level patency information [<xref ref-type="bibr" rid="c49">49</xref>].</p>
<fig id="fig1" position="float" fig-type="figure">
<label>Figure 1.</label>
<caption><title>PRISMA flowchart</title>
<p>PRISMA indicates preferred reporting items for systematic reviews and meta-analyses. N=, number of studies; n=, number of patients; TLPP, target lesion primary patency; ACPP, access circuit primary patency; IPD, individual patient data; RCT, randomized controlled trials.</p></caption>
<graphic xlink:href="20240069v1_fig1.tif"/>
</fig>
</sec>
<sec id="s3b">
<title>Study Characteristics</title>
<p>Breakdown of studies and extracted outcomes are reported in <bold><xref rid="tbl1A" ref-type="table">Table 1</xref></bold> and in <bold>Supplementary Table 2</bold> respectively. Of note: 1) 5 of the 11 studies had 20 or less patients per arm; 2) all studies had a higher percentage of males except Liao et al [<xref ref-type="bibr" rid="c47">47</xref>]; 3) a significant proportion of patients in most studies received antiplatelet treatment, either preoperatively or postoperatively; 4) 6 studies reported a significant benefit with DCB based on primary and secondary endpoints, while the other 5 found no significant difference compared with PTA; 5) 4 studies involved AVGs, of which 1 study (Liao et al [<xref ref-type="bibr" rid="c47">47</xref>]) studied only AVGs; the other 7 involved only AVFs.</p>
<table-wrap id="tbl1A" orientation="portrait" position="float">
<label>Table 1A</label>
<caption><title>Characteristics of study designs</title></caption>
<graphic xlink:href="20240069v1_tbl1A.tif"/>
<graphic xlink:href="20240069v1_tbl1A_a.tif"/>
<graphic xlink:href="20240069v1_tbl1A_b.tif"/>
<graphic xlink:href="20240069v1_tbl1A_c.tif"/>
<graphic xlink:href="20240069v1_tbl1A_d.tif"/>
<graphic xlink:href="20240069v1_tbl1A_e.tif"/>
</table-wrap>
<table-wrap id="tbl1B" orientation="portrait" position="float">
<label>Table 1B</label>
<caption><title>Patient characteristics of included studies</title></caption>
<graphic xlink:href="20240069v1_tbl1B.tif"/>
</table-wrap>
</sec>
<sec id="s3c">
<title>Reconstructed Curves</title>
<p>All included studies had IPD reconstructed from published Kaplan-Meier curves [<bold><xref rid="fig2" ref-type="fig">Figure 2</xref></bold>]. Comparisons against original Kaplan-Meier curves are shown in <bold>Supplementary Comparisons 1 &#x0026; 2</bold>. The reconstructed dataset is available on request.</p>
<fig id="fig2" position="float" fig-type="figure">
<label>Figure 2.</label>
<caption><title>Reconstructed Curves</title>
<p>DCB, drug coated balloon; PTA, percutaneous transluminal angioplasty.</p></caption>
<graphic xlink:href="20240069v1_fig2.tif"/>
</fig>
</sec>
<sec id="s3d">
<title>Quality Assessment of Trials</title>
<p>Our risk-of-bias analysis [<bold><xref rid="tbl2" ref-type="table">Table 2</xref></bold>] yielded overall &#x2018;some concerns&#x2019; for all 11 studies. As all studies were single-blinded or non-blinded, they ran the risk of observer bias, wherein knowledge of which patients were assigned DCB or PTA might have influenced the judging of outcomes. Particularly, decisions on the need for reintervention in all studies may have been influenced by knowledge of assignment to treatment or control arm, since the reinterventions in most studies involved clinical evaluation of graft dysfunction. Our JBI analysis [<bold>Supplementary Table 3</bold>] noted that Bj&#x00F6;rkman et al [<xref ref-type="bibr" rid="c44">44</xref>] discontinued their trial after only 39 patients were recruited, despite requiring a sample size of 140 in their initial power calculations.</p>
<table-wrap id="tbl2" orientation="portrait" position="float">
<label>Table 2.</label>
<caption><title>Quality Assessment of Trials: Cochrane risk of bias (ROB) assessment of randomized controlled trials</title></caption>
<graphic xlink:href="20240069v1_tbl2.tif"/>
</table-wrap>
</sec>
<sec id="s3e">
<title>Survival Outcomes</title>
<sec id="s3e1">
<title>Target Lesion Primary Patency</title>
<p>Among 10 RCTs comprising 1,207 patients, the stratified and gamma-frailty models yielded HRs in favour of DCB (shared-frailty HR=0.62, 95&#x0025;-CI: 0.53&#x2013;0.73, P&#x003C;0.001; stratified HR=0.62, 95&#x0025;-CI: 0.53&#x2013;0.73, P&#x003C;0.001) [<bold><xref rid="fig3" ref-type="fig">Figure 3</xref></bold>]. Patency rates at intervals of 6-months are reported in <bold><xref rid="fig3" ref-type="fig">Figure 3</xref></bold>.</p>
<fig id="fig3" position="float" fig-type="figure">
<label>Figure 3.</label>
<caption><title>Kaplan-Meier plot and number-at-risk table for target lesion primary patency</title>
<p>HR, hazard ratio; 95CI, 95&#x0025; confidence intervals; DCB, drug coated balloon; PTA, percutaneous transluminal angioplasty.</p></caption>
<graphic xlink:href="20240069v1_fig3.tif"/>
</fig>
<p>While time-varying effects were noted (Grambsch-Therneau test, P=0.005) [<bold>Supplementary Figure 1A</bold>], dynamic RMST curves demonstrate that DCB is consistently favoured throughout the follow-up period [<bold><xref rid="fig4" ref-type="fig">Figure 4A, B</xref></bold>].</p>
<fig id="fig4" position="float" fig-type="figure">
<label>Figure 4.</label>
<caption><title>(A) Dynamic RMST Ratios (B) Dynamic RMST Differences for Target Lesion Primary Patency (C) Two-stage Frequentist meta-analysis for target lesion primary patency</title>
<p>RMST-R, restricted mean survival time ratio; RMST-D, restricted mean survival time difference; HR, hazard ratio; 95CI, 95&#x0025; confidence intervals; DCB, drug coated balloon; PTA, percutaneous transluminal angioplasty.</p></caption>
<graphic xlink:href="20240069v1_fig4.tif"/>
<graphic xlink:href="20240069v1_fig4a.tif"/>
</fig>
<p>This was consistent within a two-stage Frequentist random-effects model (HR=0.60, 95&#x0025;-CI: 0.42&#x2013;0.86, P=0.018, <italic>I</italic><sup><italic>2</italic></sup>=65&#x0025;) [<bold><xref rid="fig4" ref-type="fig">Figure 4C</xref></bold>]. The funnel plot was visually symmetrical and did not suggest publication bias (Egger&#x2019;s test = 0.507) [<bold>Supplementary Figure 4A</bold>].</p>
</sec>
<sec id="s3e2">
<title>Access Circuit Primary Patency</title>
<p>Among 6 RCTs comprising 854 patients, the stratified and gamma-frailty models yielded HRs in favour of DCB (shared-frailty HR=0.72, 95&#x0025;-CI: 0.60&#x2013;0.87, P&#x003C;0.001; stratified HR=0.72, 95&#x0025;-CI: 0.60&#x2013;0.86, P&#x003C;0.001) [<bold><xref rid="fig5" ref-type="fig">Figure 5A</xref></bold>]. Time-varying effects were not found (Grambsch-Therneau test, P=0.300) [<bold>Supplementary Figure 1B</bold>]. Patency rates at intervals of 6-months are reported in <bold><xref rid="fig5" ref-type="fig">Figure 5A</xref></bold>.</p>
<fig id="fig5" position="float" fig-type="figure">
<label>Figure 5.</label>
<caption><title>(A) Kaplan-Meier plot and number-at-risk table for access circuit primary patency (B) Two-stage Frequentist meta-analysis for access circuit primary patency (C) Two-stage Frequentist meta-analysis for access circuit primary patency excluding outliers</title>
<p>HR, hazard ratio; 95CI, 95&#x0025; confidence intervals; DCB, drug coated balloon; PTA, percutaneous transluminal angioplasty.</p></caption>
<graphic xlink:href="20240069v1_fig5a.tif"/>
<graphic xlink:href="20240069v1_fig5b.tif"/>
<graphic xlink:href="20240069v1_fig5c.tif"/>
</fig>
<p>This was inconsistent within the overall two-stage Frequentist random-effects model (HR=0.76, 95&#x0025;-CI: 0.35&#x2013;1.67, P=0.414, <italic>I</italic><sup><italic>2</italic></sup>=81&#x0025;) [<bold><xref rid="fig5" ref-type="fig">Figure 5B</xref></bold>]. In view of the considerable heterogeneity found, we undertook efforts to identify potential outliers. The Baujat plot suggested that Bj&#x00F6;rkman et al [<xref ref-type="bibr" rid="c44">44</xref>] contributed to the most between-study heterogeneity [<bold>Supplementary Figure 5A</bold>]. At cut-offs proposed by Viechtbauer and Cheung [<xref ref-type="bibr" rid="c35">35</xref>], Bj&#x00F6;rkman et al was likewise detected as an influential case [<bold>Supplementary Figure 5B</bold>]. Leave-one-out analyses showed that omission of Bj&#x00F6;rkman et al yielded the least between-study heterogeneity (<italic>I</italic><sup>2</sup>=62&#x0025;) [<bold>Supplementary Figure 5C</bold>].</p>
<p>Sensitivity analysis excluding Bj&#x00F6;rkman et al significantly favoured DCB (two-stage Frequentist random-effects model HR=0.61, 95&#x0025;-CI: 0.41&#x2013;0.91, P=0.027, <italic>I</italic><sup><italic>2</italic></sup>=62&#x0025;) [<bold><xref rid="fig5" ref-type="fig">Figure 5C</xref></bold>]. The one-stage model excluding this study yielded congruent results with one-stage meta-analysis of the overall cohort [<bold>Supplementary Figure 6</bold>]. The funnel plot was visually asymmetrical and suggestive of publication bias [<bold>Supplementary Figure 4B</bold>].</p>
</sec>
<sec id="s3e3">
<title>Frequentist Network Meta-Analysis of Paclitaxel Concentrations</title>
<p>6 RCTs comprising 1,050 patients were included in a network meta-analysis to evaluate TLPP within a random-effects Frequentist setting (<italic>I</italic><sup><italic>2</italic></sup>=56.1&#x0025;). Among all comparisons against PTA, only DCB 3.5&#x03BC;g/mm<sup>2</sup> (HR=0.37, 95&#x0025;-CI: 0.17&#x2013;0.80, P=0.012) and DCB 3.0&#x03BC;g/mm<sup>2</sup> (HR=0.52, 95&#x0025;-CI: 0.34&#x2013;0.80, P=0.002) had a statistically significant TLPP advantage [<bold><xref rid="tbl3" ref-type="table">Table 3</xref></bold>]. Indirect comparisons between DCB 3.5&#x03BC;g/mm<sup>2</sup> and DCB 3.0&#x03BC;g/mm<sup>2</sup> showed no differences (HR=0.71, 95&#x0025;-CI: 0.29&#x2013;1.70, P=0.437) [<bold><xref rid="tbl3" ref-type="table">Table 3</xref></bold>].</p>
<table-wrap id="tbl3" orientation="portrait" position="float">
<label>Table 3.</label>
<caption><title>Frequentist Network Meta-Analysis</title></caption>
<graphic xlink:href="20240069v1_tbl3.tif"/>
</table-wrap>
<p>3 RCTs comprising 736 patients were included in a network meta-analysis to evaluate ACPP within a random-effects Frequentist setting. Heterogeneity was not estimable. Bj&#x00F6;rkman et al was excluded from this analysis in view of the upstream influence analysis. Among all comparisons against PTA, only DCB 3.5&#x03BC;g/mm<sup>2</sup> (HR=2.34, 95&#x0025;-CI: 1.59&#x2013;3.45, P&#x003C;0.001) had a statistically significant ACPP advantage [<bold><xref rid="tbl3" ref-type="table">Table 3</xref></bold>]. Indirect comparisons between DCB 3.5&#x03BC;g/mm<sup>2</sup> and DCB 2.0&#x03BC;g/mm<sup>2</sup> was significantly in favour of DCB 3.5&#x03BC;g/mm<sup>2</sup> (HR=2.09, 95&#x0025;-CI: 1.30&#x2013;3.36, P=0.002) [<bold><xref rid="tbl3" ref-type="table">Table 3</xref></bold>].</p>
<p>The comparison adjusted funnel plots were symmetrical [<bold>Supplementary Figure 7</bold>]. Within the network meta-analysis, we surmise that the transitivity assumption was likely to be met, based on the observations that the common treatment (PTA) was reasonably consistent across trials, effect modifiers were equally distributed across studies, and participants may, in principle, be randomized to any of the treatments being compared in the network. Given the star shaped nature of our network of treatment arms, statistical inconsistency could not be evaluated [<bold>Supplementary Figure 8</bold>].</p>
</sec>
<sec id="s3e4">
<title>Meta-Regression</title>
<p>Meta-regression of proportions of males, diabetics, arteriovenous fistulas and publication year against logarithmic transformed HRs for TLPP did not demonstrate any significant associations [<bold><xref rid="tbl4" ref-type="table">Table 4</xref></bold>]. Meta-regression for variables against ACPP between DCB and PTA was not conducted as there were insufficient studies.</p>
<table-wrap id="tbl4" orientation="portrait" position="float">
<label>Table 4.</label>
<caption><title>Two-Stage Meta-Regression (Target Lesion Primary Patency)</title></caption>
<graphic xlink:href="20240069v1_tbl4.tif"/>
</table-wrap>
</sec>
</sec>
</sec>
<sec id="s4">
<title>Discussion</title>
<p>In view of cost [<xref ref-type="bibr" rid="c41">41</xref>, <xref ref-type="bibr" rid="c50">50</xref>], potential morbidity [<xref ref-type="bibr" rid="c51">51</xref>] and uncertain theoretical benefit in prolonging patency rates, DCB angioplasty has yet to earn its place as the &#x201C;holy grail&#x201D; for dysfunctional hemodialysis venous access [<xref ref-type="bibr" rid="c52">52</xref>]. In 2019, in a meta-analysis of RCTs and retrospective studies by Wee et al [<xref ref-type="bibr" rid="c12">12</xref>], DCB was concluded to be superior to PTA (6-month TLPP RR=0.57, 95&#x0025;-CI: 0.44-0.74, P&#x003C;0.0001). In contrast, in a 2020 meta-analysis by Liao et al [<xref ref-type="bibr" rid="c14">14</xref>], DCB did not demonstrate significant patency benefit (6-month TLPP RR=0.75, 95&#x0025;-CI: 0.56-1.01, P=0.06), even in the AVF-only subgroup.</p>
<p>Between the randomized trials conducted, significant heterogeneity was quantitatively, and qualitatively noted with regard to patient recruitment and access details &#x2013; rendering the interpretation of its authentic efficacy challenging. Devices utilized (from IN.PACT Admiral, Passeo-Lux and Lutonix) varied in a multitude of aspects; such as its excipient, a chemical added to locally retain paclitaxel at the intended site of action.</p>
<p>Amidst this unresolved backdrop, this patient-level meta-analysis of 11 RCTs comprising 1,243 patients presents a statistically robust and up-to-date pool of evidence demonstrating a consistent benefit of using DCB over PTA in prolonging TLPP.</p>
<p>Despite incorporating random-effects shared-frailties and stratification to account for clinical heterogeneity within the one-stage model, patients treated with DCB were at a lower hazard rate of restenosis. Sensitivity analyses with aggregate data within a random-effects Frequentist models likewise re-affirm the upstream findings. In view of the violation of the proportionality assumption, dynamic restricted mean survival times consistently favoured DCB across the follow-up period. Collectively, these strongly suggest that the benefit of paclitaxel is likely a reflection of a true biological phenomenon, attesting to its superiority to plain old balloon angioplasty.</p>
<p>Albeit the promising outcomes in prolonging TLPP, comparisons of ACPP in the overall two-stage Frequentist random-effects model showed no significant differences as opposed to the significant differences demonstrated within one-stage models. Nonetheless, sensitivity analysis excluding outliers significantly favoured DCB in both one &#x0026; two-stage models.</p>
<p>Other factors which are not directly related to the target lesion may cause eventual dysfunction elsewhere in the circuit. Perhaps, the puncture of AVGs and AVFs during the procedure could cause platelet thrombi and cytokine release; even though in most instances antiplatelets are given, gradually causing vessel stenosis [<xref ref-type="bibr" rid="c3">3</xref>]. Additional lesions in the dialysis circuit may also have formed over time, resulting in reduced circuit patency [<xref ref-type="bibr" rid="c53">53</xref>].</p>
<p>In particular, Bj&#x00F6;rkman et al [<xref ref-type="bibr" rid="c44">44</xref>] heavily favoured PTA over DCB in the setting of ACPP. Bj&#x00F6;rkman et al postulated that the younger and more immature AVFs (&#x003C;1 year compared to the other studies) were more venous than arterial in nature; and with thinner venous walls, local paclitaxel overdose and potential toxicity could be more pronounced, accounting for the poor performance in the DCB arm. The authors stated that the study was discontinued due to slow recruitment; it was also limited by a smaller sample size than necessary for statistical power calculations, slow randomization and possibility of type I error. Insufficient studies provided information on age of AVFs to elucidate an association between age of AVFs and DCB efficacy in our study.</p>
<p>Looking forward, it is critical to determine the optimal concentration of paclitaxel where benefits are best observed. As suggested by the wide intervals between ranking P-Scores, there seems to be some evidence that higher concentrations of paclitaxel may be associated with longer TLPP and ACPP. Of note, among all comparisons against PTA, only DCBs with paclitaxel concentrations of 3.5&#x03BC;g/mm<sup>2</sup> and 3.0&#x03BC;g/mm<sup>2</sup> had a statistically significant TLPP advantage. However, upon closer inspection of indirect treatment comparisons generated through the Frequentist network meta-analysis, we did not find a significant difference in TLPP between concentrations of 2.0, 3.0 and 3.5&#x03BC;g/mm<sup>2</sup>.</p>
<p>While specific and potentially influential lesion covariates (such as length, location, type/location of access point and balloon diameter) were not consistently accounted for amongst the RCTs, this may suggest that the true benefit of adding paclitaxel may lie beyond concentrations beyond 3.0&#x03BC;g/mm<sup>2</sup> &#x2013; and may be an area of inquiry for further investigations.</p>
<sec id="s4a">
<title>Limitations</title>
<p>This study was not without limitations. In the course of our analyses, we were unable to account for competing risks to restenosis, such as patient mortality, for which previous studies yielded mixed findings. A DCB trial in femoropopliteal stenosis [<xref ref-type="bibr" rid="c10">10</xref>] showed increased mortality compared to PTA (24-month fixed-effect RR=1.74, 95&#x0025;-CI: 1.08-2.81, P=0.02), and a meta-analysis of paclitaxel-coated devices demonstrated an increased mortality by 4.6&#x0025; at 5-years [<xref ref-type="bibr" rid="c51">51</xref>]. That being said, a meta-analysis of paclitaxel-coated devices in dialysis access [<xref ref-type="bibr" rid="c54">54</xref>] found no difference in short to midterm mortality among patients compared to PTA (RR=1.26, 95&#x0025;-CI: 0.85-1.89, P=0.25).</p>
<p>Additionally, although IPD was recovered graphically, the reconstruction algorithm is unable to retrieve patient-level covariate information, which may offer beneficial insight if adjusted for in models utilised. Potentially prognostic covariates for restenosis include vascular access age (as mentioned above), type of access point (AVF or AVG &#x2013; where the absence of vascular smooth muscle in AVGs may prevent paclitaxel from exerting its desired action), diabetes mellitus [<xref ref-type="bibr" rid="c55">55</xref>], lesion length [<xref ref-type="bibr" rid="c56">56</xref>], blood flow volume [<xref ref-type="bibr" rid="c57">57</xref>], location of the AVF or AVG (forearm versus arm) [<xref ref-type="bibr" rid="c58">58</xref>], and type or duration of antiplatelet treatment [<xref ref-type="bibr" rid="c59">59</xref>]. Unfortunately, not all studies reported these parameters; there was hence inadequate data for us to perform a meta-regression.</p>
<p>Finally, clinical judgement to proceed with either DCB or PTA should be considered alongside the side effects of paclitaxel, procedure-related morbidity and cost-benefit analysis which are beyond the scope of this forum.</p>
</sec>
</sec>
<sec id="s5">
<title>Conclusion</title>
<p>Hereto, we present the first patient-level, RCT-only meta-analysis comparing DCB to PTA in hemodialysis access restenosis. Pooled-analyses of 11 RCTs comprising 1,243 patients &#x2013; including 2 recent RCTs published in 2020 &#x2013; demonstrate that the overall evidence suggests that DCB is favoured over PTA in prolonging TLPP and ACPP.</p>
<p>Intriguingly, we also found some evidence that higher paclitaxel concentrations may be associated with longer TLPP. Future investigations may benefit from exploring more dose-efficacy relationships and may benefit from adjusting for more lesion specific covariates such as age, length, location, type and balloon diameter.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material>
<label>Supplementary Materials</label>
<media xlink:href="supplements/240069_file12.docx" />
</supplementary-material>
<supplementary-material>
<label>Supplementary Comparisons 1</label>
<media xlink:href="supplements/240069_file13.pdf" />
</supplementary-material>
<supplementary-material>
<label>Supplementary Comparisons 2</label>
<media xlink:href="supplements/240069_file14.pdf" />
</supplementary-material>
</sec>
</body>
<back>
<sec sec-type="data-availability">
<title>Data Availability</title>
<p>This manuscript makes use of publicly-available data from published studies, therefore no original or additional data is available for sharing.</p>
</sec>
<sec id="s6">
<title>DISCLOSURE</title>
<sec id="s6a">
<title>Funding</title>
<p>None.</p>
</sec>
<sec id="s6b">
<title>Conflict of interest</title>
<p>J.J.Z. is supported by the SingHealth SMSTDA Talent Development Award administered by SingHealth, Singapore and NUS Enterprise Innovation and Entrepreneurship Practicum Award awarded by National University of Singapore, Singapore.</p>
</sec>
<sec id="s6c">
<title>Contributions</title>
<p>Study design: C.W.T., J.J.Z., K.Y.F.</p>
<p>Data collection: K.Y.F., J.J.Z., E.T.</p>
<p>Statistical analysis: J.J.Z., R.S., N.S., E.T.</p>
<p>Manuscript writing: K.Y.F., J.J.Z.</p>
<p>Critical revision of manuscript: all authors.</p>
<p>Study supervision: C.W.T.</p>
</sec>
<sec id="s6d">
<title>Data Sharing Policy</title>
<p>This manuscript makes use of publicly-available data from published studies, therefore no original or additional data is available for sharing.</p>
</sec>
<sec id="s6e">
<title>Ethics</title>
<p>Not applicable.</p>
</sec>
</sec>
<ref-list>
<title>REFERENCES</title>
<ref id="c1"><label>[1]</label><mixed-citation publication-type="journal"><string-name><given-names>M. C.</given-names> <surname>Riella</surname></string-name> and <string-name><given-names>P.</given-names> <surname>Roy-Chaudhury</surname></string-name>, &#x201C;<article-title>Vascular access in haemodialysis: strengthening the Achilles&#x2019; heel</article-title>,&#x201D; <source>Nature Reviews Nephrology</source>, vol. <volume>9</volume>, no. <issue>6</issue>, pp. <fpage>348</fpage>-<lpage>357</lpage>, 2013/06/01 <year>2013</year>, doi: <pub-id pub-id-type="doi">10.1038/nrneph.2013.76</pub-id>.</mixed-citation></ref>
<ref id="c2"><label>[2]</label><mixed-citation publication-type="journal"><string-name><given-names>C. E.</given-names> <surname>Lok</surname></string-name> <etal>et al.</etal>, &#x201C;<article-title>KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update</article-title>,&#x201D; <source>American Journal of Kidney Diseases</source>, vol. <volume>75</volume>, no. <issue>4</issue>, pp. <fpage>S1</fpage>&#x2013;<lpage>S164</lpage>, <year>2020</year>, doi: <pub-id pub-id-type="doi">10.1053/j.ajkd.2019.12.001</pub-id>.</mixed-citation></ref>
<ref id="c3"><label>[3]</label><mixed-citation publication-type="journal"><string-name><given-names>P.</given-names> <surname>Roy-Chaudhury</surname></string-name>, <string-name><given-names>V. P.</given-names> <surname>Sukhatme</surname></string-name>, and <string-name><given-names>A. K.</given-names> <surname>Cheung</surname></string-name>, &#x201C;<article-title>Hemodialysis Vascular Access Dysfunction: A Cellular and Molecular Viewpoint</article-title>,&#x201D; <source>Journal of the American Society of Nephrology</source>, vol. <volume>17</volume>, no. <issue>4</issue>, p. <fpage>1112</fpage>, <year>2006</year>, doi: <pub-id pub-id-type="doi">10.1681/ASN.2005050615</pub-id>.</mixed-citation></ref>
<ref id="c4"><label>[4]</label><mixed-citation publication-type="journal"><string-name><given-names>A.</given-names> <surname>Mima</surname></string-name>, &#x201C;<article-title>Hemodialysis Vascular Access Dysfunction: Molecular Mechanisms and Treatment</article-title>,&#x201D; <source>Therapeutic Apheresis and Dialysis</source>, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1744-9987.2012.01066.x">https://doi.org/10.1111/j.1744-9987.2012.01066.x</ext-link> vol. <volume>16</volume>, no. <issue>4</issue>, pp. <fpage>321</fpage>-<lpage>327</lpage>, 2012/08/01 <year>2012</year>, doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1744-9987.2012.01066.x">https://doi.org/10.1111/j.1744-9987.2012.01066.x</ext-link>.</mixed-citation></ref>
<ref id="c5"><label>[5]</label><mixed-citation publication-type="journal"><string-name><given-names>T.</given-names> <surname>Lee</surname></string-name> and <string-name><given-names>N. Ul</given-names> <surname>Haq</surname></string-name>, &#x201C;<article-title>New Developments in Our Understanding of Neointimal Hyperplasia,&#x201D; (in eng)</article-title>, <source>Advances in chronic kidney disease</source>, vol. <volume>22</volume>, no. <issue>6</issue>, pp. <fpage>431</fpage>&#x2013;<lpage>7</lpage>, <month>Nov</month> <year>2015</year>, doi: <pub-id pub-id-type="doi">10.1053/j.ackd.2015.06.010</pub-id>.</mixed-citation></ref>
<ref id="c6"><label>[6]</label><mixed-citation publication-type="journal"><string-name><given-names>K.</given-names> <surname>Maeda</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Furukawa</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Yamasaki</surname></string-name>, and <string-name><given-names>K.</given-names> <surname>Murata</surname></string-name>, &#x201C;<article-title>Percutaneous transluminal angioplasty for Brescia-Cimino hemodialysis fistula dysfunction: technical success rate, patency rate and factors that influence the results,&#x201D; (in eng)</article-title>, <source>Eur J Radiol</source>, vol. <volume>54</volume>, no. <issue>3</issue>, pp. <fpage>426</fpage>&#x2013;<lpage>30</lpage>, <month>Jun</month> <year>2005</year>, doi: <pub-id pub-id-type="doi">10.1016/j.ejrad.2004.07.011</pub-id>.</mixed-citation></ref>
<ref id="c7"><label>[7]</label><mixed-citation publication-type="journal"><string-name><given-names>B. H.</given-names> <surname>Lee</surname></string-name> <etal>et al.</etal>, &#x201C;<article-title>Paclitaxel-coated expanded polytetrafluoroethylene haemodialysis grafts inhibit neointimal hyperplasia in porcine model of graft stenosis</article-title>,&#x201D; <source>Nephrology Dialysis Transplantation</source>, vol. <volume>21</volume>, no. <issue>9</issue>, pp. <fpage>2432</fpage>&#x2013;<lpage>2438</lpage>, <year>2006</year>, doi: <pub-id pub-id-type="doi">10.1093/ndt/gfl070</pub-id>.</mixed-citation></ref>
<ref id="c8"><label>[8]</label><mixed-citation publication-type="journal"><string-name><given-names>T.</given-names> <surname>Masaki</surname></string-name> <etal>et al.</etal>, &#x201C;<article-title>Inhibition of neointimal hyperplasia in vascular grafts by sustained perivascular delivery of paclitaxel</article-title>,&#x201D; <source>Kidney International</source>, vol. <volume>66</volume>, no. <issue>5</issue>, pp. <fpage>2061</fpage>-<lpage>2069</lpage>, 2004/11/01/ <year>2004, doi</year>: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1523-1755.2004.00985.x">https://doi.org/10.1111/j.1523-1755.2004.00985.x</ext-link>.</mixed-citation></ref>
<ref id="c9"><label>[9]</label><mixed-citation publication-type="journal"><string-name><given-names>W. Heldman</given-names> <surname>Alan</surname></string-name> <etal>et al.</etal>, &#x201C;<article-title>Paclitaxel Stent Coating Inhibits Neointimal Hyperplasia at 4 Weeks in a Porcine Model of Coronary Restenosis</article-title>,&#x201D; <source>Circulation</source>, vol. <volume>103</volume>, no. <issue>18</issue>, pp. <fpage>2289</fpage>-<lpage>2295</lpage>, 2001/05/08 <year>2001</year>, doi: <pub-id pub-id-type="doi">10.1161/01.CIR.103.18.2289</pub-id>.</mixed-citation></ref>
<ref id="c10"><label>[10]</label><mixed-citation publication-type="journal"><string-name><given-names>C.</given-names> <surname>Klumb</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Lehmann</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Aschenbach</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Eckardt</surname></string-name>, and <string-name><given-names>U.</given-names> <surname>Teichgr&#x00E4;ber</surname></string-name>, &#x201C;<article-title>Benefit and risk from paclitaxel-coated balloon angioplasty for the treatment of femoropopliteal artery disease: A systematic review and meta-analysis of randomised controlled trials</article-title>,&#x201D; <source>EClinicalMedicine</source>, vol. <volume>16</volume>, pp. <fpage>42</fpage>&#x2013;<lpage>50</lpage>, <year>2019</year>, doi: <pub-id pub-id-type="doi">10.1016/j.eclinm.2019.09.004</pub-id>.</mixed-citation></ref>
<ref id="c11"><label>[11]</label><mixed-citation publication-type="journal"><string-name><given-names>B.</given-names> <surname>Scheller</surname></string-name> <etal>et al.</etal>, &#x201C;<article-title>Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter</article-title>,&#x201D; <source>Clinical Research in Cardiology</source>, vol. <volume>97</volume>, no. <issue>10</issue>, pp. <fpage>773</fpage>-<lpage>781</lpage>, 2008/10/01 <year>2008</year>, doi: <pub-id pub-id-type="doi">10.1007/s00392-008-0682-5</pub-id>.</mixed-citation></ref>
<ref id="c12"><label>[12]</label><mixed-citation publication-type="journal"><string-name><given-names>I. J. Yan</given-names> <surname>Wee</surname></string-name> <etal>et al.</etal>, &#x201C;<article-title>A systematic review and meta-analysis of drug-coated balloon versus conventional balloon angioplasty for dialysis access stenosis</article-title>,&#x201D; <source>Journal of Vascular Surgery</source>, vol. <volume>70</volume>, no. <issue>3</issue>, pp. <fpage>970</fpage>-<lpage>979</lpage>.e3, <year>2019</year>, doi: <pub-id pub-id-type="doi">10.1016/j.jvs.2019.01.082</pub-id>.</mixed-citation></ref>
<ref id="c13"><label>[13]</label><mixed-citation publication-type="journal"><string-name><given-names>S. A.</given-names> <surname>Kennedy</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Mafeld</surname></string-name>, <string-name><given-names>M. O.</given-names> <surname>Baerlocher</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Jaberi</surname></string-name>, and <string-name><given-names>D. K.</given-names> <surname>Rajan</surname></string-name>, &#x201C;<article-title>Drug-Coated Balloon Angioplasty in Hemodialysis Circuits: A Systematic Review and Meta-Analysis</article-title>,&#x201D; <source>Journal of Vascular and Interventional Radiology</source>, vol. <volume>30</volume>, no. <issue>4</issue>, pp. <fpage>483</fpage>-<lpage>494</lpage>.e1, <year>2019</year>, doi: <pub-id pub-id-type="doi">10.1016/j.jvir.2019.01.012</pub-id>.</mixed-citation></ref>
<ref id="c14"><label>[14]</label><mixed-citation publication-type="journal"><string-name><given-names>M.-T.</given-names> <surname>Liao</surname></string-name> <etal>et al.</etal>, &#x201C;<article-title>Drug-coated balloon versus conventional balloon angioplasty of hemodialysis arteriovenous fistula or graft: A systematic review and meta-analysis of randomized controlled trials</article-title>,&#x201D; <source>PLOS ONE</source>, vol. <volume>15</volume>, no. <issue>4</issue>, p. <fpage>e0231463</fpage>, <year>2020</year>, doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0231463</pub-id>.</mixed-citation></ref>
<ref id="c15"><label>[15]</label><mixed-citation publication-type="journal"><string-name><given-names>S. Abdul</given-names> <surname>Salim</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Tran</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Thongprayoon</surname></string-name>, <string-name><given-names>T.</given-names> <surname>F&#x00FC;l&#x00F6;p</surname></string-name>, and <string-name><given-names>W.</given-names> <surname>Cheungpasitporn</surname></string-name>, &#x201C;<article-title>Comparison of drug-coated balloon angioplasty versus conventional angioplasty for arteriovenous fistula stenosis: Systematic review and meta-analysis</article-title>,&#x201D; <source>The Journal of Vascular Access</source>, vol. <volume>21</volume>, no. <issue>3</issue>, pp. <fpage>357</fpage>-<lpage>365</lpage>, 2020/05/01 <year>2019</year>, doi: <pub-id pub-id-type="doi">10.1177/1129729819878612</pub-id>.</mixed-citation></ref>
<ref id="c16"><label>[16]</label><mixed-citation publication-type="journal"><string-name><given-names>R. A.</given-names> <surname>Lookstein</surname></string-name> <etal>et al.</etal>, &#x201C;<article-title>Drug-Coated Balloons for Dysfunctional Dialysis Arteriovenous Fistulas</article-title>,&#x201D; <source>New England Journal of Medicine</source>, vol. <volume>383</volume>, no. <issue>8</issue>, pp. <fpage>733</fpage>-<lpage>742</lpage>, 2020/08/20 <year>2020</year>, doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1914617</pub-id>.</mixed-citation></ref>
<ref id="c17"><label>[17]</label><mixed-citation publication-type="journal"><string-name><given-names>J. W.</given-names> <surname>Kim</surname></string-name>, <string-name><given-names>J. H.</given-names> <surname>Kim</surname></string-name>, <string-name><given-names>S. S.</given-names> <surname>Byun</surname></string-name>, <string-name><given-names>J. M.</given-names> <surname>Kang</surname></string-name>, and <string-name><given-names>J. H.</given-names> <surname>Shin</surname></string-name>, &#x201C;<article-title>Paclitaxel-Coated Balloon versus Plain Balloon Angioplasty for Dysfunctional Autogenous Radiocephalic Arteriovenous Fistulas: A Prospective Randomized Controlled Trial</article-title>,&#x201D; <source>Korean J Radiol</source>, vol. <volume>21</volume>, no. <issue>11</issue>, pp. <fpage>1239</fpage>-<lpage>1247</lpage>, 11/ <year>2020. [Online]. Available</year>: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3348/kjr.2020.0067">https://doi.org/10.3348/kjr.2020.0067</ext-link>.</mixed-citation></ref>
<ref id="c18"><label>[18]</label><mixed-citation publication-type="journal"><string-name><given-names>P.</given-names> <surname>Guyot</surname></string-name>, <string-name><given-names>A. E.</given-names> <surname>Ades</surname></string-name>, <string-name><given-names>M. J. N. M.</given-names> <surname>Ouwens</surname></string-name>, and <string-name><given-names>N. J.</given-names> <surname>Welton</surname></string-name>, &#x201C;<article-title>Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves</article-title>,&#x201D; <source>BMC Medical Research Methodology</source>, vol. <volume>12</volume>, no. <issue>1</issue>, p. <fpage>9</fpage>, 2012/02/01 <year>2012</year>, doi: <pub-id pub-id-type="doi">10.1186/1471-2288-12-9</pub-id>.</mixed-citation></ref>
<ref id="c19"><label>[19]</label><mixed-citation publication-type="journal"><string-name><given-names>Y.</given-names> <surname>Wei</surname></string-name> and <string-name><given-names>P.</given-names> <surname>Royston</surname></string-name>, &#x201C;<article-title>Reconstructing time-to-event data from published Kaplan-Meier curves,&#x201D; (in eng)</article-title>, <source>Stata J</source>, vol. <volume>17</volume>, no. <issue>4</issue>, pp. <fpage>786</fpage>&#x2013;<lpage>802</lpage>, <year>2017. [Online]. Available</year>: <ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/29398980">https://pubmed.ncbi.nlm.nih.gov/29398980</ext-link> <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796634/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796634/</ext-link>.</mixed-citation></ref>
<ref id="c20"><label>[20]</label><mixed-citation publication-type="journal"><string-name><given-names>R. D.</given-names> <surname>Riley</surname></string-name>, <string-name><given-names>P. C.</given-names> <surname>Lambert</surname></string-name>, and <string-name><given-names>G.</given-names> <surname>Abo-Zaid</surname></string-name>, &#x201C;<article-title>Meta-analysis of individual participant data: rationale, conduct, and reporting</article-title>,&#x201D; <source>BMJ</source>, vol. <volume>340</volume>, p. <fpage>c221</fpage>, <year>2010</year>, doi: <pub-id pub-id-type="doi">10.1136/bmj.c221</pub-id>.</mixed-citation></ref>
<ref id="c21"><label>[21]</label><mixed-citation publication-type="journal"><string-name><given-names>M. C.</given-names> <surname>Simmonds</surname></string-name>, <string-name><given-names>J. P.</given-names> <surname>Higgins</surname></string-name>, <string-name><given-names>L. A.</given-names> <surname>Stewart</surname></string-name>, <string-name><given-names>J. F.</given-names> <surname>Tierney</surname></string-name>, <string-name><given-names>M. J.</given-names> <surname>Clarke</surname></string-name>, and <string-name><given-names>S. G.</given-names> <surname>Thompson</surname></string-name>, &#x201C;<article-title>Meta-analysis of individual patient data from randomized trials: a review of methods used in practice,&#x201D; (in eng)</article-title>, <source>Clin Trials</source>, vol. <volume>2</volume>, no. <issue>3</issue>, pp. <fpage>209</fpage>&#x2013;<lpage>17</lpage>, <year>2005</year>, doi: <pub-id pub-id-type="doi">10.1191/1740774505cn087oa</pub-id>.</mixed-citation></ref>
<ref id="c22"><label>[22]</label><mixed-citation publication-type="journal"><string-name><given-names>L. A.</given-names> <surname>Stewart</surname></string-name> <etal>et al.</etal>, &#x201C;<article-title>Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement,&#x201D; (in eng)</article-title>, <source>Jama</source>, vol. <volume>313</volume>, no. <issue>16</issue>, pp. <fpage>1657</fpage>&#x2013;<lpage>65</lpage>, <month>Apr</month> 28 <year>2015</year>, doi: <pub-id pub-id-type="doi">10.1001/jama.2015.3656</pub-id>.</mixed-citation></ref>
<ref id="c23"><label>[23]</label><mixed-citation publication-type="journal"><string-name><given-names>B.</given-names> <surname>Hutton</surname></string-name> <etal>et al.</etal>, &#x201C;<article-title>The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations</article-title>,&#x201D; <source>Annals of Internal Medicine</source>, vol. <volume>162</volume>, no. <issue>11</issue>, pp. <fpage>777</fpage>-<lpage>784</lpage>, 2015/06/02 <year>2015</year>, doi: <pub-id pub-id-type="doi">10.7326/M14-2385</pub-id>.</mixed-citation></ref>
<ref id="c24"><label>[24]</label><mixed-citation publication-type="book"><string-name><given-names>J. A. C.</given-names> <surname>Sterne</surname></string-name> <etal>et al.</etal>, &#x201C;<chapter-title>RoB 2: a revised tool for assessing risk of bias in randomised trials</chapter-title>,&#x201D; <source>BMJ</source>, vol. <volume>366</volume>, p. <publisher-loc>4898</publisher-loc>, <year>2019</year>, doi: <pub-id pub-id-type="doi">10.1136/bmj.l4898</pub-id>.</mixed-citation></ref>
<ref id="c25"><label>[25]</label><mixed-citation publication-type="journal"><string-name><given-names>Z.</given-names> <surname>Munn</surname></string-name> <etal>et al.</etal>, &#x201C;<article-title>The development of software to support multiple systematic review types: the Joanna Briggs Institute System for the Unified Management, Assessment and Review of Information (JBI SUMARI)</article-title>,&#x201D; <source>JBI Evidence Implementation</source>, vol. <volume>17</volume>, no. <issue>1</issue>, <year>2019. [Online]. Available</year>: <ext-link ext-link-type="uri" xlink:href="https://journals.lww.com/ijebh/Fulltext/2019/03000/The_development_of_software_to_support_multiple.5.aspx">https://journals.lww.com/ijebh/Fulltext/2019/03000/The_development_of_software_to_support_multiple.5.aspx</ext-link>.</mixed-citation></ref>
<ref id="c26"><label>[26]</label><mixed-citation publication-type="journal"><string-name><given-names>D.</given-names> <surname>Schoenfeld</surname></string-name>, &#x201C;<article-title>Partial residuals for the proportional hazards regression model</article-title>,&#x201D; <source>Biometrika</source>, vol. <volume>69</volume>, no. <issue>1</issue>, pp. <fpage>239</fpage>&#x2013;<lpage>241</lpage>, <year>1982</year>, doi: <pub-id pub-id-type="doi">10.1093/biomet/69.1.239</pub-id>.</mixed-citation></ref>
<ref id="c27"><label>[27]</label><mixed-citation publication-type="journal"><string-name><given-names>P. M.</given-names> <surname>Grambsch</surname></string-name> and <string-name><given-names>T. M.</given-names> <surname>Therneau</surname></string-name>, &#x201C;<article-title>Proportional hazards tests and diagnostics based on weighted residuals</article-title>,&#x201D; <source>Biometrika</source>, vol. <volume>81</volume>, no. <issue>3</issue>, pp. <fpage>515</fpage>&#x2013;<lpage>526</lpage>, <year>1994</year>, doi: <pub-id pub-id-type="doi">10.1093/biomet/81.3.515</pub-id>.</mixed-citation></ref>
<ref id="c28"><label>[28]</label><mixed-citation publication-type="journal"><string-name><given-names>H.</given-names> <surname>Uno</surname></string-name> <etal>et al.</etal>, &#x201C;<article-title>Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis,&#x201D; (in eng)</article-title>, <source>J Clin Oncol</source>, vol. <volume>32</volume>, no. <issue>22</issue>, pp. <fpage>2380</fpage>&#x2013;<lpage>5</lpage>, <month>Aug</month> 1 <year>2014</year>, doi: <pub-id pub-id-type="doi">10.1200/jco.2014.55.2208</pub-id>.</mixed-citation></ref>
<ref id="c29"><label>[29]</label><mixed-citation publication-type="journal"><string-name><given-names>H.</given-names> <surname>Uno</surname></string-name> <etal>et al.</etal>, &#x201C;<article-title>Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies,&#x201D; (in eng)</article-title>, <source>Ann Intern Med</source>, vol. <volume>163</volume>, no. <issue>2</issue>, pp. <fpage>127</fpage>&#x2013;<lpage>34</lpage>, <month>Jul</month> 21 <year>2015</year>, doi: <pub-id pub-id-type="doi">10.7326/m14-1741</pub-id>.</mixed-citation></ref>
<ref id="c30"><label>[30]</label><mixed-citation publication-type="journal"><string-name><given-names>J. J. Z.</given-names> <surname>Liao</surname></string-name>, <string-name><given-names>G. F.</given-names> <surname>Liu</surname></string-name>, and <string-name><given-names>W.-C.</given-names> <surname>Wu</surname></string-name>, &#x201C;<article-title>Dynamic RMST curves for survival analysis in clinical trials</article-title>,&#x201D; <source>BMC Medical Research Methodology</source>, vol. <volume>20</volume>, no. <issue>1</issue>, p. <fpage>218</fpage>, 2020/08/27 <year>2020</year>, doi: <pub-id pub-id-type="doi">10.1186/s12874-020-01098-5</pub-id>.</mixed-citation></ref>
<ref id="c31"><label>[31]</label><mixed-citation publication-type="journal"><string-name><given-names>M.</given-names> <surname>Othus</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Barlogie</surname></string-name>, <string-name><given-names>M. L.</given-names> <surname>LeBlanc</surname></string-name>, and <string-name><given-names>J. J.</given-names> <surname>Crowley</surname></string-name>, &#x201C;<article-title>Cure Models as a Useful Statistical Tool for Analyzing Survival</article-title>,&#x201D; <source>Clinical Cancer Research</source>, vol. <volume>18</volume>, no. <issue>14</issue>, pp. <fpage>3731</fpage>&#x2013;<lpage>3736</lpage>, <year>2012</year>, doi: <pub-id pub-id-type="doi">10.1158/1078-0432.Ccr-11-2859</pub-id>.</mixed-citation></ref>
<ref id="c32"><label>[32]</label><mixed-citation publication-type="journal"><string-name><given-names>M.</given-names> <surname>Egger</surname></string-name>, <string-name><given-names>G. D.</given-names> <surname>Smith</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Schneider</surname></string-name>, and <string-name><given-names>C.</given-names> <surname>Minder</surname></string-name>, &#x201C;<article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>,&#x201D; <source>BMJ</source>, vol. <volume>315</volume>, no. <issue>7109</issue>, p. <fpage>629</fpage>, <year>1997</year>, doi: <pub-id pub-id-type="doi">10.1136/bmj.315.7109.629</pub-id>.</mixed-citation></ref>
<ref id="c33"><label>[33]</label><mixed-citation publication-type="website"><string-name><given-names>T. J.</given-names> <surname>Higgins JPT</surname></string-name>, <string-name><surname>Chandler</surname> <given-names>J</given-names></string-name>, <string-name><surname>Cumpston</surname> <given-names>M</given-names></string-name>, <string-name><surname>Li</surname> <given-names>T</given-names></string-name>, <string-name><surname>Page</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Welch</surname> <given-names>VA</given-names></string-name> (editors). <article-title>Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020)</article-title>. <source>Cochrane</source>, <year>2020</year>. Available from <ext-link ext-link-type="uri" xlink:href="http://www.training.cochrane.org/handbook">www.training.cochrane.org/handbook</ext-link>. (accessed.</mixed-citation></ref>
<ref id="c34"><label>[34]</label><mixed-citation publication-type="journal"><string-name><given-names>J. P.</given-names> <surname>Higgins</surname></string-name>, <string-name><given-names>S. G.</given-names> <surname>Thompson</surname></string-name>, <string-name><given-names>J. J.</given-names> <surname>Deeks</surname></string-name>, and <string-name><given-names>D. G.</given-names> <surname>Altman</surname></string-name>, &#x201C;<article-title>Measuring inconsistency in meta-analyses,&#x201D; (in eng)</article-title>, <source>Bmj</source>, vol. <volume>327</volume>, no. <issue>7414</issue>, pp. <fpage>557</fpage>&#x2013;<lpage>60</lpage>, <month>Sep</month> 6 <year>2003</year>, doi: <pub-id pub-id-type="doi">10.1136/bmj.327.7414.557</pub-id>.</mixed-citation></ref>
<ref id="c35"><label>[35]</label><mixed-citation publication-type="journal"><string-name><given-names>W.</given-names> <surname>Viechtbauer</surname></string-name> and <string-name><given-names>M. W. L.</given-names> <surname>Cheung</surname></string-name>, &#x201C;<article-title>Outlier and influence diagnostics for meta-analysis</article-title>,&#x201D; <source>Research Synthesis Methods</source>, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/jrsm.11">https://doi.org/10.1002/jrsm.11</ext-link> vol. <volume>1</volume>, no. <issue>2</issue>, pp. <fpage>112</fpage>-<lpage>125</lpage>, 2010/04/01 <year>2010, doi</year>: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/jrsm.11">https://doi.org/10.1002/jrsm.11</ext-link>.</mixed-citation></ref>
<ref id="c36"><label>[36]</label><mixed-citation publication-type="journal"><string-name><given-names>B.</given-names> <surname>Baujat</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Mah&#x00E9;</surname></string-name>, <string-name><given-names>J. P.</given-names> <surname>Pignon</surname></string-name>, and <string-name><given-names>C.</given-names> <surname>Hill</surname></string-name>, &#x201C;<article-title>A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials,&#x201D; (in eng)</article-title>, <source>Statistics in medicine</source>, vol. <volume>21</volume>, no. <issue>18</issue>, pp. <fpage>2641</fpage>&#x2013;<lpage>52</lpage>, <month>Sep</month> 30 <year>2002</year>, doi: <pub-id pub-id-type="doi">10.1002/sim.1221</pub-id>.</mixed-citation></ref>
<ref id="c37"><label>[37]</label><mixed-citation publication-type="journal"><string-name><given-names>G.</given-names> <surname>Rucker</surname></string-name> and <string-name><given-names>G.</given-names> <surname>Schwarzer</surname></string-name>, &#x201C;<article-title>Ranking treatments in frequentist network meta-analysis works without resampling methods,&#x201D; (in eng)</article-title>, <source>BMC Med Res Methodol</source>, vol. <volume>15</volume>, p. <fpage>58</fpage>, <month>Jul</month> 31 <year>2015</year>, doi: <pub-id pub-id-type="doi">10.1186/s12874-015-0060-8</pub-id>.</mixed-citation></ref>
<ref id="c38"><label>[38]</label><mixed-citation publication-type="journal"><string-name><given-names>S. P.</given-names> <surname>Hozo</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Djulbegovic</surname></string-name>, and <string-name><given-names>I.</given-names> <surname>Hozo</surname></string-name>, &#x201C;<article-title>Estimating the mean and variance from the median, range, and the size of a sample</article-title>,&#x201D; <source>BMC Medical Research Methodology</source>, vol. <volume>5</volume>, no. <issue>1</issue>, p. <fpage>13</fpage>, 2005/04/20 <year>2005</year>, doi: <pub-id pub-id-type="doi">10.1186/1471-2288-5-13</pub-id>.</mixed-citation></ref>
<ref id="c39"><label>[39]</label><mixed-citation publication-type="journal"><string-name><given-names>X.</given-names> <surname>Wan</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Liu</surname></string-name>, and <string-name><given-names>T.</given-names> <surname>Tong</surname></string-name>, &#x201C;<article-title>Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range</article-title>,&#x201D; <source>BMC Medical Research Methodology</source>, vol. <volume>14</volume>, no. <issue>1</issue>, p. <fpage>135</fpage>, 2014/12/19 <year>2014</year>, doi: <pub-id pub-id-type="doi">10.1186/1471-2288-14-135</pub-id>.</mixed-citation></ref>
<ref id="c40"><label>[40]</label><mixed-citation publication-type="journal"><string-name><given-names>T. A.</given-names> <surname>Furukawa</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Barbui</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Cipriani</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Brambilla</surname></string-name>, and <string-name><given-names>N.</given-names> <surname>Watanabe</surname></string-name>, &#x201C;<article-title>Imputing missing standard deviations in meta-analyses can provide accurate results,&#x201D; (in eng)</article-title>, <source>J Clin Epidemiol</source>, vol. <volume>59</volume>, no. <issue>1</issue>, pp. <fpage>7</fpage>&#x2013;<lpage>10</lpage>, <month>Jan</month> <year>2006</year>, doi: <pub-id pub-id-type="doi">10.1016/j.jclinepi.2005.06.006</pub-id>.</mixed-citation></ref>
<ref id="c41"><label>[41]</label><mixed-citation publication-type="journal"><string-name><given-names>P. M.</given-names> <surname>Kitrou</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Spiliopoulos</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Katsanos</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Papachristou</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Siablis</surname></string-name>, and <string-name><given-names>D.</given-names> <surname>Karnabatidis</surname></string-name>, &#x201C;<article-title>Paclitaxel-Coated versus Plain Balloon Angioplasty for Dysfunctional Arteriovenous Fistulae: One-Year Results of a Prospective Randomized Controlled Trial</article-title>,&#x201D; <source>Journal of Vascular and Interventional Radiology</source>, vol. <volume>26</volume>, no. <issue>3</issue>, pp. <fpage>348</fpage>&#x2013;<lpage>354</lpage>, <year>2015</year>, doi: <pub-id pub-id-type="doi">10.1016/j.jvir.2014.11.003</pub-id>.</mixed-citation></ref>
<ref id="c42"><label>[42]</label><mixed-citation publication-type="journal"><string-name><given-names>L. J.</given-names> <surname>Roosen</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Karamermer</surname></string-name>, <string-name><given-names>J. A.</given-names> <surname>Vos</surname></string-name>, <string-name><given-names>G. M.</given-names> <surname>Jong</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Bos</surname></string-name>, and <string-name><given-names>O. E.</given-names> <surname>Elgersma</surname></string-name>, &#x201C;<article-title>Paclitaxel-coated balloons do not prevent recurrent stenosis in hemodialysis access fistulae: Results of a randomized clinical trial</article-title>,&#x201D; <source>Italian Journal of Vascular and Endovascular Surgery</source>, vol. <volume>24</volume>, pp. <fpage>35</fpage>-<lpage>40</lpage>, 06/01 <year>2017</year>, doi: <pub-id pub-id-type="doi">10.23736/S1824-4777.17.01282-7</pub-id>.</mixed-citation></ref>
<ref id="c43"><label>[43]</label><mixed-citation publication-type="journal"><string-name><given-names>S. O.</given-names> <surname>Trerotola</surname></string-name>, <string-name><given-names>T. F.</given-names> <surname>Saad</surname></string-name>, and <string-name><given-names>P.</given-names> <surname>Roy-Chaudhury</surname></string-name><article-title>, &#x201C;The Lutonix AV Randomized Trial of Paclitaxel-Coated Balloons in Arteriovenous Fistula Stenosis: 2-Year Results and Subgroup Analysis,&#x201D;</article-title> <source>Journal of Vascular and Interventional Radiology</source>, vol. <volume>31</volume>, no. <issue>1</issue>, pp. <fpage>1</fpage>-<lpage>14</lpage>.e5, <year>2020</year>, doi: <pub-id pub-id-type="doi">10.1016/j.jvir.2019.08.035</pub-id>.</mixed-citation></ref>
<ref id="c44"><label>[44]</label><mixed-citation publication-type="journal"><string-name><given-names>P.</given-names> <surname>Bj&#x00F6;rkman</surname></string-name>, <string-name><given-names>E.-M.</given-names> <surname>Weselius</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Kokkonen</surname></string-name>, <string-name><given-names>V.</given-names> <surname>Rauta</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Alb&#x00E4;ck</surname></string-name>, and <string-name><given-names>M.</given-names> <surname>Venermo</surname></string-name>, &#x201C;<article-title>Drug-Coated Versus Plain Balloon Angioplasty In Arteriovenous Fistulas: A Randomized, Controlled Study With 1-Year Follow-Up (The Drecorest Ii-Study)</article-title>,&#x201D; <source>Scandinavian Journal of Surgery</source>, vol. <volume>108</volume>, p. <fpage>145749691879820</fpage>, 09/05 <year>2018</year>, doi: <pub-id pub-id-type="doi">10.1177/1457496918798206</pub-id>.</mixed-citation></ref>
<ref id="c45"><label>[45]</label><mixed-citation publication-type="journal"><string-name><given-names>J. J.</given-names> <surname>Swinnen</surname></string-name> <etal>et al.</etal>, &#x201C;<article-title>Multicentre, randomised, blinded, control trial of drug-eluting balloon vs Sham in recurrent native dialysis fistula stenoses</article-title>,&#x201D; <source>The Journal of Vascular Access</source>, vol. <volume>20</volume>, no. <issue>3</issue>, pp. <fpage>260</fpage>-<lpage>269</lpage>, 2019/05/01 <year>2018</year>, doi: <pub-id pub-id-type="doi">10.1177/1129729818801556</pub-id>.</mixed-citation></ref>
<ref id="c46"><label>[46]</label><mixed-citation publication-type="journal"><string-name><given-names>F. G.</given-names> <surname>Irani</surname></string-name> <etal>et al.</etal>, &#x201C;<article-title>Hemodialysis Arteriovenous Fistula and Graft Stenoses: Randomized Trial Comparing Drug-eluting Balloon Angioplasty with Conventional Angioplasty</article-title>,&#x201D; <source>Radiology</source>, vol. <volume>289</volume>, no. <issue>1</issue>, pp. <fpage>238</fpage>-<lpage>247</lpage>, 2018/10/01 <year>2018</year>, doi: <pub-id pub-id-type="doi">10.1148/radiol.2018170806</pub-id>.</mixed-citation></ref>
<ref id="c47"><label>[47]</label><mixed-citation publication-type="journal"><string-name><given-names>M.-T.</given-names> <surname>Liao</surname></string-name> <etal>et al.</etal>, &#x201C;<article-title>A randomized controlled trial of drug-coated balloon angioplasty in venous anastomotic stenosis of dialysis arteriovenous grafts</article-title>,&#x201D; <source>Journal of Vascular Surgery</source>, vol. <volume>71</volume>, no. <issue>6</issue>, pp. <fpage>1994</fpage>&#x2013;<lpage>2003</lpage>, <year>2020</year>, doi: <pub-id pub-id-type="doi">10.1016/j.jvs.2019.07.090</pub-id>.</mixed-citation></ref>
<ref id="c48"><label>[48]</label><mixed-citation publication-type="journal"><string-name><given-names>T.</given-names> <surname>Moreno-S&#x00E1;nchez</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Moreno-Ram&#x00ED;rez</surname></string-name>, <string-name><given-names>F. H.</given-names> <surname>Machancoses</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Pardo-Moreno</surname></string-name>, <string-name><given-names>P. F.</given-names> <surname>Navarro-Vergara</surname></string-name>, and <string-name><given-names>J.</given-names> <surname>Garc&#x00ED;a-Revillo</surname></string-name>, &#x201C;<article-title>Efficacy of Paclitaxel Balloon for Hemodialysis Stenosis Fistulae After One Year Compared to High-Pressure Balloons: A Controlled, Multicenter, Randomized Trial</article-title>,&#x201D; <source>CardioVascular and Interventional Radiology</source>, vol. <volume>43</volume>, no. <issue>3</issue>, pp. <fpage>382</fpage>-<lpage>390</lpage>, 2020/03/01 <year>2020</year>, doi: <pub-id pub-id-type="doi">10.1007/s00270-019-02372-w</pub-id>.</mixed-citation></ref>
<ref id="c49"><label>[49]</label><mixed-citation publication-type="journal"><string-name><given-names>Y.</given-names> <surname>Liu</surname></string-name> <etal>et al.</etal>, &#x201C;<article-title>Comparison of macrovascular invasion-free survival in early-intermediate hepatocellular carcinoma after different interventions: A propensity score-based analysis,&#x201D; (in eng)</article-title>, <source>J Cancer</source>, vol. <volume>10</volume>, no. <issue>17</issue>, pp. <fpage>4063</fpage>&#x2013;<lpage>4071</lpage>, <year>2019</year>, doi: <pub-id pub-id-type="doi">10.7150/jca.29850</pub-id>.</mixed-citation></ref>
<ref id="c50"><label>[50]</label><mixed-citation publication-type="journal"><string-name><given-names>N. I.</given-names> <surname>Marupudi</surname></string-name>, <string-name><given-names>J. E.</given-names> <surname>Han</surname></string-name>, <string-name><given-names>K. W.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>V. M.</given-names> <surname>Renard</surname></string-name>, <string-name><given-names>B. M.</given-names> <surname>Tyler</surname></string-name>, and <string-name><given-names>H.</given-names> <surname>Brem</surname></string-name>, &#x201C;<article-title>Paclitaxel: a review of adverse toxicities and novel delivery strategies,&#x201D; (in eng)</article-title>, <source>Expert opinion on drug safety</source>, vol. <volume>6</volume>, no. <issue>5</issue>, pp. <fpage>609</fpage>&#x2013;<lpage>21</lpage>, <month>Sep</month> <year>2007</year>, doi: <pub-id pub-id-type="doi">10.1517/14740338.6.5.609</pub-id>.</mixed-citation></ref>
<ref id="c51"><label>[51]</label><mixed-citation publication-type="journal"><string-name><given-names>J.</given-names> <surname>Rocha-Singh Krishna</surname></string-name> <etal>et al.</etal>, &#x201C;<article-title>Mortality and Paclitaxel-Coated Devices</article-title>,&#x201D; <source>Circulation</source>, vol. <volume>141</volume>, no. <issue>23</issue>, pp. <fpage>1859</fpage>-<lpage>1869</lpage>, 2020/06/09 <year>2020</year>, doi: <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.119.044697</pub-id>.</mixed-citation></ref>
<ref id="c52"><label>[52]</label><mixed-citation publication-type="other"><string-name><given-names>F. G.</given-names> <surname>Irani</surname></string-name> and <string-name><given-names>B. S.</given-names> <surname>Tan</surname></string-name>, &#x201C;<article-title>Drug Coated Balloons: Are they the Holy Grail for Dysfunctional Dialysis Arteriovenous Fistulas?</article-title>,&#x201D; <source>CardioVascular and Interventional Radiology, 2020/11/06</source> <year>2020</year>, doi: <pub-id pub-id-type="doi">10.1007/s00270-020-02690-4</pub-id>.</mixed-citation></ref>
<ref id="c53"><label>[53]</label><mixed-citation publication-type="journal"><string-name><given-names>M. R.</given-names> <surname>Chan</surname></string-name>, <string-name><given-names>H. N.</given-names> <surname>Young</surname></string-name>, and <string-name><given-names>A. S.</given-names> <surname>Yevzlin</surname></string-name>, &#x201C;<article-title>The effect of in-stent restenosis on hemodialysis access patency</article-title>,&#x201D; <source>Hemodialysis International</source>, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1542-4758.2009.00389.x">https://doi.org/10.1111/j.1542-4758.2009.00389.x</ext-link> xvol. <volume>13</volume>, no. <issue>3</issue>, pp. <fpage>250</fpage>-<lpage>256</lpage>, 2009/07/01 <year>2009, doi</year>: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1542-4758.2009.00389.x">https://doi.org/10.1111/j.1542-4758.2009.00389.x</ext-link>.</mixed-citation></ref>
<ref id="c54"><label>[54]</label><mixed-citation publication-type="journal"><string-name><given-names>K.</given-names> <surname>Dinh</surname></string-name> <etal>et al.</etal>, &#x201C;<article-title>Mortality After Paclitaxel-Coated Device Use in Dialysis Access: A Systematic Review and Meta-Analysis</article-title>,&#x201D; <source>Journal of Endovascular Therapy</source>, vol. <volume>26</volume>, no. <issue>5</issue>, pp. <fpage>600</fpage>-<lpage>612</lpage>, 2019/10/01 <year>2019</year>, doi: <pub-id pub-id-type="doi">10.1177/1526602819872154</pub-id>.</mixed-citation></ref>
<ref id="c55"><label>[55]</label><mixed-citation publication-type="journal"><string-name><given-names>F. C.</given-names> <surname>Prischl</surname></string-name> <etal>et al.</etal>, &#x201C;<article-title>Parameters of prognostic relevance to the patency of vascular access in hemodialysis patients</article-title>,&#x201D; <source>Journal of the American Society of Nephrology</source>, vol. <volume>6</volume>, no. <issue>6</issue>, p. <fpage>1613</fpage>, <year>1995. [Online]. Available</year>: <ext-link ext-link-type="uri" xlink:href="http://jasn.asnjournals.org/content/6/6/1613.abstract">http://jasn.asnjournals.org/content/6/6/1613.abstract</ext-link>.</mixed-citation></ref>
<ref id="c56"><label>[56]</label><mixed-citation publication-type="journal"><string-name><given-names>T. W. I.</given-names> <surname>Clark</surname></string-name>, <string-name><given-names>D. A.</given-names> <surname>Hirsch</surname></string-name>, <string-name><given-names>K. J.</given-names> <surname>Jindal</surname></string-name>, <string-name><given-names>P. J.</given-names> <surname>Veugelers</surname></string-name>, and <string-name><given-names>J.</given-names> <surname>LeBlanc</surname></string-name>, &#x201C;<article-title>Outcome and Prognostic Factors of Restenosis after Percutaneous Treatment of Native Hemodialysis Fistulas</article-title>,&#x201D; <source>Journal of Vascular and Interventional Radiology</source>, vol. <volume>13</volume>, no. <issue>1</issue>, pp. <fpage>51</fpage>-<lpage>59</lpage>, 2002/01/01/ <year>2002, doi</year>: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S1051-0443(07)60009-8">https://doi.org/10.1016/S1051-0443(07)60009-8</ext-link>.</mixed-citation></ref>
<ref id="c57"><label>[57]</label><mixed-citation publication-type="journal"><string-name><given-names>K.</given-names> <surname>Miyamoto</surname></string-name> <etal>et al.</etal>, &#x201C;<article-title>Analysis of factors for post&#x2013;percutaneous transluminal angioplasty primary patency rate in hemodialysis vascular access</article-title>,&#x201D; <source>The Journal of Vascular Access</source>, vol. <volume>21</volume>, no. <issue>6</issue>, pp. <fpage>892</fpage>-<lpage>899</lpage>, 2020/11/01 <year>2020</year>, doi: <pub-id pub-id-type="doi">10.1177/1129729820910555</pub-id>.</mixed-citation></ref>
<ref id="c58"><label>[58]</label><mixed-citation publication-type="journal"><string-name><given-names>M.</given-names> <surname>Monroy-Cuadros</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Yilmaz</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Salazar-Ba&#x00F1;uelos</surname></string-name>, and <string-name><given-names>C.</given-names> <surname>Doig</surname></string-name>, &#x201C;<article-title>Risk Factors Associated with Patency Loss of Hemodialysis Vascular Access within 6 Months</article-title>,&#x201D; <source>Clinical Journal of the American Society of Nephrology</source>, vol. <volume>5</volume>, no. <issue>10</issue>, p. <fpage>1787</fpage>, <year>2010</year>, doi: <pub-id pub-id-type="doi">10.2215/CJN.09441209</pub-id>.</mixed-citation></ref>
<ref id="c59"><label>[59]</label><mixed-citation publication-type="journal"><string-name><given-names>C.-C.</given-names> <surname>Lin</surname></string-name> and <string-name><given-names>W.-C.</given-names> <surname>Yang</surname></string-name>, &#x201C;<article-title>Prognostic Factors Influencing the Patency of Hemodialysis Vascular Access: Literature Review and Novel Therapeutic Modality by Far Infrared Therapy</article-title>,&#x201D; <source>Journal of the Chinese Medical Association</source>, vol. <volume>72</volume>, no. <issue>3</issue>, pp. <fpage>109</fpage>-<lpage>116</lpage>, 2009/03/01/ <year>2009, doi</year>: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S1726-4901(09)70035-8">https://doi.org/10.1016/S1726-4901(09)70035-8</ext-link>.</mixed-citation></ref>
</ref-list>
<sec id="s7">
<title>PRISMA-IPD Checklist of items to include when reporting a systematic review and meta-analysis of individual participant data (IPD)</title>
<table-wrap id="utbl1" orientation="portrait" position="float">
<graphic xlink:href="20240069v1_utbl1.tif"/>
<graphic xlink:href="20240069v1_utbl1a.tif"/>
<graphic xlink:href="20240069v1_utbl1b.tif"/>
<graphic xlink:href="20240069v1_utbl1c.tif"/>
</table-wrap>
</sec>
<sec id="s8">
<title>PRISMA NMA Checklist of Items to Include When Reporting A Systematic Review Involving a Network Meta-analysis</title>
<table-wrap id="utbl2" orientation="portrait" position="float">
<graphic xlink:href="20240069v1_utbl2.tif"/>
<graphic xlink:href="20240069v1_utbl2a.tif"/>
<graphic xlink:href="20240069v1_utbl2c.tif"/>
<graphic xlink:href="20240069v1_utbl2d.tif"/>
</table-wrap>
</sec>
</back>
</article>